Breaking News

Helsinn Establishes New R&D Hub in the U.S.

To support clinical work across its Global Fully Integrated Targeted Therapy (FITT) Strategy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Helsinn Group, a global biopharma company with a pipeline of innovative oncology assets, has established a new dedicated R&D hub at its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc. (HTU), that augments Helsinn Group’s global R&D organization. As a result of the updated licensing agreement with BridgeBio Pharma Inc. announced in March 2022, Helsinn is creating a new R&D hub to support a significant expected increase in clinical activities for developing the FGFR tyrosine kinase...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters